The Journal Of Clinical And Aesthetic Dermatology Published Arcutis Biotherapeutics' Outcomes Of A Comprehensive Evaluation By An Expert Dermatologist Panel Assessing The Formulation Ingredients Of ZORYVE Topical Foam, 0.3%
The Journal Of Clinical And Aesthetic Dermatology Published Arcutis Biotherapeutics' Outcomes Of A Comprehensive Evaluation By An Expert Dermatologist Panel Assessing The Formulation Ingredients Of ZORYVE Topical Foam, 0.3%
- Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation data
- Crodafos CES, used in ZORYVE foam, is suitable for a wide variety of skin and hair types
- Findings from this formulation review underscore the suitability of ZORYVE foam for use on all affected areas of the body, and all hair types, in the management of seborrheic dermatitis
- 根据对配方数据的审查，九位专家中有八位对向不同皮肤和头发类型的患者（包括以前接受过头发治疗的患者）开ZORYVE泡沫剂处方表示 “非常有信心”
- Crodafos CES 用于 ZORYVE 泡沫，适用于各种皮肤和头发类型
- 本次配方审查的结果突显了ZORYVE泡沫适用于治疗脂溢性皮炎的身体所有受影响部位和所有头发类型
WESTLAKE VILLAGE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Journal of Clinical and Aesthetic Dermatology (JCAD) published the outcomes of a comprehensive evaluation by an expert dermatologist panel assessing the formulation ingredients of ZORYVE (roflumilast) topical foam, 0.3%. ZORYVE foam is a once-daily steroid-free treatment for seborrheic dermatitis. The published article supports the use of ZORYVE foam in all hair and skin types.
加利福尼亚州西湖村，2024年5月13日（GLOBE NEWSWIRE）——专注于开发有意义的免疫皮肤病学创新的商业阶段生物制药公司Arcutis Biotherapeutics, Inc.（纳斯达克股票代码：ARQT）今天宣布 临床与美容皮肤病学杂志 （JCAD）公布了专业皮肤科专家小组对ZORYVE（roflumilast）局部泡沫的配方成分进行的一项综合评估的结果，占0.3％。ZORYVE 泡沫是一种每日一次的无类固醇治疗脂溢性皮炎的药物。发表的文章支持在所有头发和皮肤类型中使用ZORYVE泡沫。